| 1 | State of Arkansas | As Engrossed: H3/14/17 | |
|----|-----------------------------------|--|------------------------|
| 2 | 91st General Assembly | A Bill | |
| 3 | Regular Session, 2017 | | HOUSE BILL 2059 |
| 4 | | | |
| 5 | By: Representative Hammer | | |
| 6 | | | |
| 7 | | For An Act To Be Entitled | |
| 8 | AN ACT TO | AMEND THE PRESCRIPTION DRUG MONIT | TORING |
| 9 | PROGRAM; 7 | TO CREATE THE PRESCRIPTION DRUG A | BUSE |
| 10 | REDUCTION | ACT; AND FOR OTHER PURPOSES. | |
| 11 | | | |
| 12 | | | |
| 13 | | Subtitle | |
| 14 | TO A | MEND THE PRESCRIPTION DRUG MONITO | RING |
| 15 | PROG | RAM; AND TO CREATE THE PRESCRIPTI | ON |
| 16 | DRUG | ABUSE REDUCTION ACT. | |
| 17 | | | |
| 18 | | | |
| 19 | BE IT ENACTED BY THE O | GENERAL ASSEMBLY OF THE STATE OF A | ARKANSAS: |
| 20 | | | |
| 21 | SECTION 1. DO 1 | NOT CODIFY. <u>Title.</u> | |
| 22 | <u>This act shall l</u> | be known and may be cited as the | "Prescription Drug |
| 23 | Abuse Reduction Act." | | |
| 24 | | | |
| 25 | SECTION 2. Arke | ansas Code § 20-7-604(d), concern | ing the requirements |
| 26 | for the Prescription l | Drug Monitoring Program, is amendo | ed to read as follows: |
| 27 | (d) <u>(l)</u> Practit | ioners Except as required in subd | ivision (d)(2) of this |
| 28 | section, practitioners | s are encouraged to access or chec | ck the information in |
| 29 | the controlled substan | nce database created under this s | ubchapter before |
| 30 | prescribing, dispensi | ng, or administering medications. | |
| 31 | <u>(2)(A)</u> A | prescriber shall check the inform | mation in the |
| 32 | Prescription Drug Mon | itoring Program when prescribing: | |
| 33 | | (i) An opioid from Schedule I. | I or Schedule III for |
| 34 | every time prescribing | g the medication to a patient; and | <u>d</u> |
| 35 | | (ii) A benzodiazepine medicat | ion for the first time |
| 36 | prescribing the medica | ation to a patient. | |

As Engrossed: H3/14/17 HB2059

| 1 | (B) A licensing board that licenses practitioners who have | | |
|----|---|--|--|
| 2 | the authority to prescribe shall adopt rules requiring the practitioners to | | |
| 3 | check the information in the Prescription Drug Monitoring Program as | | |
| 4 | described in subdivision (d)(2) of this section. | | |
| 5 | (C) This subdivision (d)(2) does not apply to: | | |
| 6 | (i) A practitioner administering a controlled | | |
| 7 | substance: | | |
| 8 | (a) Immediately before or during surgery; | | |
| 9 | (b) During recovery from a surgery while in a | | |
| 10 | healthcare facility; | | |
| 11 | (c) In a healthcare facility; or | | |
| 12 | (d) Necessary to treat a patient in an | | |
| 13 | emergency situation at the scene of an emergency, in a licensed ground | | |
| 14 | ambulance or air ambulance, or in the intensive care unit of a licensed | | |
| 15 | hospital; | | |
| 16 | (ii) A practitioner prescribing or administering a | | |
| 17 | controlled substance to: | | |
| 18 | (a) A palliative care or hospice patient; or | | |
| 19 | (b) A resident in a licensed nursing home | | |
| 20 | <u>facility; or</u> | | |
| 21 | (iii) Situations in which the Prescription Drug | | |
| 22 | Monitoring Program is not accessible due to technological or electrical | | |
| 23 | <u>failure.</u> | | |
| 24 | (3) A licensed oncologist shall check the Prescription Drug | | |
| 25 | Monitoring Program when prescribing to a patient on an initial malignate | | |
| 26 | episodic diagnosis and every three (3) months following the diagnosis while | | |
| 27 | continuing treatment. | | |
| 28 | | | |
| 29 | SECTION 3. Arkansas Code § 20-7-607(a)(1), concerning providing | | |
| 30 | prescription monitoring information to the Prescription Drug Monitoring | | |
| 31 | Program, is amended to read as follows: | | |
| 32 | (a)(1)(A) $\underline{(i)}$ The Department of Health \underline{may} \underline{shall} review the | | |
| 33 | Prescription Drug Monitoring Program information, including without | | |
| 34 | limitation a review to identify information that appears to indicate whether | | |
| 35 | a person <u>may be</u> <u>is</u> obtaining prescriptions in a manner that may represent | | |
| 36 | misuse or abuse of controlled substances <u>based on prescribing criteria</u> | | |

As Engrossed: H3/14/17 HB2059

| 1 | determined by the Director of the Department of Health upon consultation with |
|----|---|
| 2 | the Prescription Drug Monitoring Program Advisory Committee. |
| 3 | (ii) The prescribing criteria shall be posted on the |
| 4 | website of the department and be available in print upon request. |
| 5 | (B) If the information appears to indicate misuse or abuse |
| 6 | may have occurred, the department shall notify the practitioners and |
| 7 | dispensers who have prescribed or dispensed in the following manner: |
| 8 | (i) The department shall provide quarterly reports |
| 9 | to the individual practitioners and dispensers; and |
| 10 | (ii) If after twelve (12) months of providing |
| 11 | quarterly reports to the practitioners and dispensers, the information |
| 12 | appears to indicate misuse or abuse may be continuing, the department shall |
| 13 | send a report to the licensing boards of the practitioner or dispenser who |
| 14 | prescribed or dispensed the prescription. |
| 15 | (C) If information of misuse or abuse is identified, the |
| 16 | department shall notify the practitioners and dispensers who prescribed or |
| 17 | dispensed the prescriptions and the Office of Diversion Control of the United |
| 18 | States Drug Enforcement Administration. |
| 19 | (D) On or before January 1, 2019, the department shall |
| 20 | contract with a vendor to make the Prescription Drug Monitoring Program |
| 21 | interactive and to provide same-day reporting in real-time, if funding and |
| 22 | technology are available. |
| 23 | |
| 24 | SECTION 4. Arkansas Code § 20-7-611, concerning unlawful acts and |
| 25 | penalties regarding the Prescription Drug Monitoring Program, is amended to |
| 26 | add an additional subsection to read as follows: |
| 27 | (i) A practitioner who purposely fails to access the Prescription Drug |
| 28 | Monitoring Program as required by § 20-7-604(d) is subject to disciplinary |
| 29 | action by the licensing board of the practitioner. |
| 30 | |
| 31 | |
| 32 | /s/Hammer |
| 33 | |
| 34 | |
| 35 | |
| 36 | |